Document is current
Any future updates will be listed below
-
Authors
Rojas, Luis A. https://orcid.org/0000-0001-9218-4086
Sethna, Zachary
Soares, Kevin C. https://orcid.org/0000-0002-0406-017X
Olcese, Cristina
Pang, Nan
Patterson, Erin
Lihm, Jayon
Ceglia, Nicholas
Guasp, Pablo https://orcid.org/0000-0002-3655-916X
Chu, Alexander
Yu, Rebecca
Chandra, Adrienne Kaya
Waters, Theresa
Ruan, Jennifer
Amisaki, Masataka https://orcid.org/0000-0003-4153-4036
Zebboudj, Abderezak https://orcid.org/0000-0002-4708-5211
Odgerel, Zagaa
Payne, George
Derhovanessian, Evelyna
Müller, Felicitas
Rhee, Ina
Yadav, Mahesh
Dobrin, Anton https://orcid.org/0000-0002-9751-0677
Sadelain, Michel https://orcid.org/0000-0002-9031-8025
Łuksza, Marta
Cohen, Noah https://orcid.org/0000-0003-3947-2585
Tang, Laura
Basturk, Olca https://orcid.org/0000-0003-2747-1366
Gönen, Mithat
Katz, Seth
Do, Richard Kinh
Epstein, Andrew S.
Momtaz, Parisa
Park, Wungki https://orcid.org/0000-0002-8006-3102
Sugarman, Ryan
Varghese, Anna M.
Won, Elizabeth
Desai, Avni
Wei, Alice C. https://orcid.org/0000-0002-2505-959X
D’Angelica, Michael I.
Kingham, T. Peter
Mellman, Ira https://orcid.org/0000-0002-6132-7299
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
Wolchok, Jedd D.
Sahin, Ugur https://orcid.org/0000-0003-0363-1564
Türeci, Özlem
Greenbaum, Benjamin D. https://orcid.org/0000-0001-6153-8793
Jarnagin, William R.
Drebin, Jeffrey
O’Reilly, Eileen M. https://orcid.org/0000-0002-8076-9199
Balachandran, Vinod P. https://orcid.org/0000-0002-2956-223X
- License Information
-
More Information
Article History
Received: 10 January 2023
Accepted: 6 April 2023
First Online: 10 May 2023
Competing interests
: L.A.R. is an inventor of a patent related to oncolytic viral therapy (US20170051022A1). L.A.R., Z.S., B.D.G. and V.P.B. are inventors on patent applications related to work on antigen cross-reactivity (PCT/US2023/011643) and tracking vaccine-expanded T cell clones. M.Ł., B.D.G. and V.P.B. are inventors on a patent application on neoantigen quality modelling (63/303,500). B.D.G. has received honoraria for speaking engagements from Merck, Bristol Meyers Squibb and Chugai Pharmaceuticals; has received research funding from Bristol Meyers Squibb, Merck, and ROME Therapeutics; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies and Rome Therapeutics of which he is a co-founder. R.K.D. received one-time consulting fees from GE Healthcare and Bayer Healthcare. A.S.E. received royalties from Up-To-Date. A.M.V. discloses the following relationships (provision of services, uncompensated): Bristol-Myers Squibb, GlaxoSmithKline, Lilly Oncology, OBI Pharma, and Silenseed. M.S. has collaborative research agreements with Atara Biotherapeutics, Fate Therapeutics, Mnemo Therapeutics, and Takeda Pharmaceuticals. A.C.W. is a consultant for Histosonics and Biosapien; received honorarium from Medtronic and AstraZeneca; and received travel support from Intuitive Surgical. T.P.K. received a one-time consulting fee from Olympus Surgical. J.D. owns stock in Alnylam Pharmaceuticals, Arrowroot Acquisition, and Ionis Pharmaceuticals. W.P. receives grant and research support from Astellas, Merck, NIH/NCI, Parker Institute for Cancer Immunotherapy, and Break Through Cancer. E.M.O. receives grant and research support from Genentech/Roche, Celgene/Bristol-Myers Squibb, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, and the NIH/NCI. T.M. is a co-founder and holds equity in IMVAQ Therapeutics; he is a consultant for Immunos Therapeutics, ImmunoGenesis and Pfizer; he has research support from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea; he has patents on applications related to work on oncolytic viral therapy, alphavirus-based vaccine, neoantigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. J.D.W. is a consultant for Apricity, CellCarta, Ascentage Pharma; AstraZeneca, Bicara Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Dragonfly, Georgiamune, Imvaq, Larkspur, Psioxus, Recepta, Tizona, and Sellas. J.D.W. receives grant and research support from Bristol-Myers Squibb and Sephora. J.D.W. has equity in Apricity, Arsenal IO, Ascentage, Imvaq, Linneaus, Georgiamune, Maverick, and Tizona Therapeutics. V.P.B. has received honoraria for speaking engagements from Genentech, and research support from Bristol-Myers Squibb and Genentech. Ö.T. and U.S. are co-founders, management board members and employees at BioNTech. E.D. and F.M. are employees at BioNTech. I.R., M.Y. and I.M. are employees at Genentech. The other authors (K.C.S., C.O., N.P., E.P., J.L., N. Ceglia, P.G., A.C., R.Y., A.K.C., T.W., J.R., M.A., A.Z., Z.O., G.P., A. Dobrin, N. Cohen, L.T., O.B., M.G., S.K., P.M., E.W., R.S., A. Desai, M.I.D. and W.R.J.) declare no competing interests.
